Fluoroescaline
Pharmaceutical compound
From Wikipedia, the free encyclopedia
Fluoroescaline (FE), also known as 4-(2-fluoroethoxy)-3,5-dimethoxyphenethylamine, is a psychedelic drug of the phenethylamine and scaline families related to mescaline.[1][2][3] It is a fluorinated derivative of escaline.[1][2][3]
- None
| |
| Clinical data | |
|---|---|
| Other names | FE; 2-Fluoroescaline; 2-FE; FEM; 4-(2-Fluoroethoxy)-3,5-dimethoxyphenethylamine; 3,5-Dimethoxy-4-(2-fluoroethoxy)phenethylamine |
| Routes of administration | Oral[1][2][3] |
| Drug class | Serotonin receptor modulator; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen |
| ATC code |
|
| Pharmacokinetic data | |
| Duration of action | ~6 hours[1][2][3] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C12H18FNO3 |
| Molar mass | 243.278 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
The drug is active at a dose of 75 mg or more orally and its duration is approximately 6 hours.[1][2][3] It has not been fully tested and it produced only weak hallucinogenic effects and no closed-eye or open-eye visuals at dose of 75 mg.[1] The drug was said to be "almost devoid of psychoactive effects", at least at the tested doses.[2] Fluoroescaline is notably less potent than escaline.[1][2][3]
It is a low-potency near-full agonist of the serotonin 5-HT2A receptor and also interacts with other serotonin receptors and targets.[3]
The chemical synthesis of fluoroescaline has been described.[4]
Fluoroescaline was first described in the scientific literature by Daniel Trachsel in 2002.[1][2][3][4] Its pharmacology was subsequently described in further detail in 2021.[3] It is not a controlled substance in Canada as of 2025.[5]